Studybox Research 510(k) Clinical Studies
Point-of-Care HbA1c Test
Clinical and analytical performance to support substantial equivalence.
Studybox
510(k) Clinical Studies
HbA1c is one of the few analytes where a global standardization program, NGSP, effectively sets the accuracy bar for every method. A point-of-care device is compared to an NGSP-traceable laboratory method, and its total error, bias plus imprecision, is judged against expectations that have tightened over time. Waived HbA1c devices have historically been limited to monitoring known diabetes; a diagnostic claim requires demonstrating accuracy and precision near the diagnostic thresholds in untrained hands, and few devices have achieved it in waived settings.
The known weakness of waived HbA1c testing is precision. Independent evaluations of point-of-care HbA1c analyzers have found that some devices fall short of laboratory precision in routine use, and that sites run by untrained operators show more variability than the manufacturer's analytical studies. A waiver study for HbA1c therefore has to show that imprecision at waived sites, with fingerstick sampling by untrained operators, stays within limits that keep the result clinically useful at decision thresholds.
- Analyte
- Hemoglobin A1c (glycated hemoglobin), reported as % HbA1c (NGSP) and mmol/mol (IFCC)
- Therapeutic area
- Cardiovascular Disease
- Specimens
- Capillary Fingerstick Blood, Venous Whole Blood
- Intended-use settings
- urgent care, physician office, pharmacy, hospital POC
- Operators
- Medical assistants, nurses and pharmacists in waived settings; laboratory staff for moderate-complexity claims.
- Comparator
- Typically an NGSP-certified laboratory HbA1c method (HPLC or similar) traceable to the NGSP secondary reference laboratory network, run on paired venous blood.
510(k) Studies specifics
What Changes for This Assay on This Pathway.
- The comparator should be NGSP-traceable and results reported in both NGSP (%) and IFCC (mmol/mol) units; the 510(k) typically includes NGSP certification of the device.
- Hemoglobin variant interference is a required analytical study and a labeling element; devices differ in whether HbS, HbC, HbE and HbD traits and elevated HbF affect them.
- A diagnostic intended use (as opposed to monitoring) requires specimens concentrated near the diagnostic thresholds and a precision claim adequate to classify patients at those thresholds.
Endpoints the study must support
- Method comparison bias (regression and difference plots) against the NGSP-traceable comparator across the measuring range, with attention to the diagnostic decision thresholds
- Imprecision (repeatability, within-site and between-site) at low, decision-threshold and high HbA1c levels
- Agreement between capillary fingerstick and venous whole blood on the device
- Interference from common hemoglobin variants (HbS, HbC, HbE, HbD) and elevated HbF
Enrollment realities
Driven by coverage of the HbA1c range rather than subject count; sites must deliberately recruit high values, and a diagnostic claim needs density near the thresholds. Precision arms add repeat visits or multiple fingersticks per subject.
How Studybox runs it
Pre-Qualified Sites, Embedded Coordinators.
Our 100+ pre-qualified U.S. sites are matched to the intended-use population and setting, with Studybox coordinators embedded on site for recruitment, consent, specimen handling, and data capture. Typical activation is about four weeks. How we run 510(k) clinical studies →
Same assay, other pathways
Relevant FDA guidance
FAQ
Point-of-Care HbA1c Test Study Questions.
01 Who operates the point-of-care hba1c test in a 510(k) studies study?
Medical assistants, nurses and pharmacists in waived settings; laboratory staff for moderate-complexity claims.
02 What is the comparator for a point-of-care hba1c test study?
Typically an NGSP-certified laboratory HbA1c method (HPLC or similar) traceable to the NGSP secondary reference laboratory network, run on paired venous blood.
03 What drives enrollment for a point-of-care hba1c test study?
Driven by coverage of the HbA1c range rather than subject count; sites must deliberately recruit high values, and a diagnostic claim needs density near the thresholds. Precision arms add repeat visits or multiple fingersticks per subject.
Let's talk IVD research
Planning a point-of-care hba1c test study?
Tell us the intended use and setting. We'll come back with a site plan, operator strategy, and a realistic activation timeline for the 510(k) studies pathway.